1p36 tumor suppression--a matter of dosage?
- PMID: 23172308
- DOI: 10.1158/0008-5472.CAN-12-2230
1p36 tumor suppression--a matter of dosage?
Abstract
A broad range of human malignancies is associated with nonrandom 1p36 deletions, suggesting the existence of tumor suppressors encoded in this region. Evidence for tumor-specific inactivation of 1p36 genes in the classic "two-hit" manner is scarce; however, many tumor suppressors do not require complete inactivation but contribute to tumorigenesis by partial impairment. We discuss recent data derived from both human tumors and functional cancer models indicating that the 1p36 genes CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a contribute to cancer development when reduced in dosage by genomic copy number loss or other mechanisms. We explore potential interactions among these candidates and propose a model where heterozygous 1p36 deletion impairs oncosuppressive pathways via simultaneous downregulation of several dosage-dependent tumor suppressor genes.
Similar articles
-
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.Clin Cancer Res. 2005 Feb 1;11(3):1119-28. Clin Cancer Res. 2005. PMID: 15709179
-
CHD5 is a tumor suppressor at human 1p36.Cell. 2007 Feb 9;128(3):459-75. doi: 10.1016/j.cell.2006.11.052. Cell. 2007. PMID: 17289567
-
Monosomy 1p36 breakpoint junctions suggest pre-meiotic breakage-fusion-bridge cycles are involved in generating terminal deletions.Hum Mol Genet. 2003 Sep 1;12(17):2153-65. doi: 10.1093/hmg/ddg231. Epub 2003 Jul 15. Hum Mol Genet. 2003. PMID: 12915474
-
The quest for the 1p36 tumor suppressor.Cancer Res. 2008 Apr 15;68(8):2551-6. doi: 10.1158/0008-5472.CAN-07-2095. Cancer Res. 2008. PMID: 18413720 Free PMC article. Review.
-
Analysis of genomic imprinting at 1p35-36 in neuroblastoma.Med Pediatr Oncol. 2001 Jan;36(1):52-5. doi: 10.1002/1096-911X(20010101)36:1<52::AID-MPO1014>3.0.CO;2-8. Med Pediatr Oncol. 2001. PMID: 11464906 Review.
Cited by
-
Mutations of 1p genes do not consistently abrogate tumor suppressor functions in 1p-intact neuroblastoma.BMC Cancer. 2022 Jun 30;22(1):717. doi: 10.1186/s12885-022-09800-0. BMC Cancer. 2022. PMID: 35768791 Free PMC article.
-
ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy.Adv Cancer Res. 2014;121:183-233. doi: 10.1016/B978-0-12-800249-0.00005-6. Adv Cancer Res. 2014. PMID: 24889532 Free PMC article. Review.
-
MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.Mol Med Rep. 2019 Jan;19(1):345-361. doi: 10.3892/mmr.2018.9686. Epub 2018 Nov 22. Mol Med Rep. 2019. PMID: 30483774 Free PMC article.
-
Identification of Casz1 as a Regulatory Protein Controlling T Helper Cell Differentiation, Inflammation, and Immunity.Front Immunol. 2018 Feb 7;9:184. doi: 10.3389/fimmu.2018.00184. eCollection 2018. Front Immunol. 2018. PMID: 29467767 Free PMC article.
-
Synergistic Action of 1,2-Epoxy-3 (3- (3,4-dimethoxyphenyl)- 4H-1-benzopiyran-4-on) Propane with Doxorubicin and Cisplatin through Increasing of p53, TIMP-3, and MicroRNA-34a in Cervical Cancer Cell Line (HeLa).Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2955-2962. doi: 10.22034/APJCP.2018.19.10.2955. Asian Pac J Cancer Prev. 2018. PMID: 30362332 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases